Compare LIND & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | NUVB |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2011 | 2020 |
| Metric | LIND | NUVB |
|---|---|---|
| Price | $28.34 | $5.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $22.25 | $11.38 |
| AVG Volume (30 Days) | 821.4K | ★ 4.3M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 71.56 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | $10.98 | $203.82 |
| Revenue Next Year | $6.98 | $58.18 |
| P/E Ratio | $394.00 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $11.37 | $3.15 |
| 52 Week High | $35.00 | $9.75 |
| Indicator | LIND | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 40.06 |
| Support Level | $24.55 | $5.28 |
| Resistance Level | $30.00 | $6.25 |
| Average True Range (ATR) | 1.17 | 0.27 |
| MACD | 0.30 | -0.06 |
| Stochastic Oscillator | 79.26 | 19.82 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.